ANSA BIOTECHNOLOGIES, INC.
Berkeley, CA · Founded 2018 · CIK 0001816722 · Biotech · Private
Enzymatic DNA synthesis system for rapid production of long, error-free DNA sequences
ansabio.com →- Grants
- $1.2M
- 2 awards
- Sector median: 1
- Raised
- $123M
- 4 Form D · Oct 2025
- 12 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 35
- 2 granted · 33 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | National Science Foundation · Phase I · SBIR Phase I: Reagent Development for a Rapid Enzymatic DNA Synthesis Platform | $225,000 | |
| Private capital raised | Form D · SEC | $4,734,242 | |
| Federal grant | National Science Foundation · Phase II · SBIR Phase II: Reagent Development for a Rapid Enzymatic DNA Synthesis Platform | $994,682 | |
| Private capital raised | Form D · SEC | $5,000,000 | |
| Private capital raised | Form D · SEC | $67,724,967 | |
| Private capital raised | Form D · SEC | $45,199,665 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2801 | Silverback Therapeutics | — | $139M |
| 2802 | VANQUA BIO, INC. | — | $136M |
| 2803 | Chroma Medicine | — | $135M |
| 2804 | ANSA BIOTECHNOLOGIES, INC. | — | $123M |
| 2805 | Frontier Medicines | — | $122M |
| 2806 | Praxis Precision Medicine | — | — |
| 2807 | Seismic Therapeutic, Inc. | — | $121M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Yanniv DoroneDirector
- Jason GammackDirector · Executive Officer
- Lily LiDirector
- Daniel Lin-ArlowDirector · Executive Officer
- Matthew McManusDirector
- Sebastian PallukDirector · Executive Officer
- Chenny ZhangDirector
Patents
- Modified Nucleotides And Nucleotide Conjugates For Polynucleotide Synthesisgranted
- Cleavable Linkers For The Tethering Of Polymerases To Nucleotidesapplication
- Directed Evolution Method For Template-independent Polymerasesapplication
- Modified Terminal Deoxynucleotidyl Transferase Polymerasesapplication
- Directed Evolution Method For Template-independent Polymerasesgranted
- Compositions For Enzymatic Polynucleotide Synthesis And Methods Of Useapplication
- Methods Of Polynucleotide Synthesisapplication
- Reversible Terminatorsapplication
- Modified Terminal Deoxynucleotidyl Transferase Polymerasesapplication
- Methods And Systems For Polymer Synthesis By Contacting Synthesis Surfaces With Compartmentalized Liquid Reagentsapplication
- Methods Of Polynucleotide Synthesisapplication
- Compositions For Enzymatic Polynucleotide Synthesis And Methods Of Useapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.